The role of negative regulators or suppressors of the damage-associated molecular patternmediated (DAMP-mediated) stimulation of innate immune responses is being increasingly appreciated. However, the presence and function of suppressors of DAMP-mediated effects on T cells, and whether they can be targeted to mitigate T cell-dependent immunopathology remain unknown. Sialic acid-binding immunoglobulin-like lectin G (Siglec-G) is a negative regulator of DAMP-mediated responses in innate immune cells, but its T cell-autonomous role is unknown. Utilizing loss-of-function-based (genetic knockout) and gain-of-function-based (agonist) approaches, we demonstrate that in the presence of certain DAMPs, Siglec-G suppressed in vitro and in vivo T cell responses. We also demonstrate that its T cell-autonomous role is critical for modulating the severity of the T cell-mediated immunopathology, graft-versus-host disease (GVHD). Enhancing the Siglec-G signaling in donor T cells with its agonist, a CD24Fc fusion protein, ameliorated GVHD while preserving sufficient graft-versus-tumor (GVT) effects in vivo. Collectively, these data demonstrate that Siglec-G is a potentially novel negative regulator of T cell responses, which can be targeted to mitigate GVHD.
Introduction
Innate immune receptors such as Toll-like receptors (TLRs) on immune cells play critical roles in initiating inflammatory responses to damage-and pathogen-associated molecular patterns (DAMPs and PAMPs, respectively) (1) . It is well understood that TLR signaling in antigen-presenting cells (APCs) enhances T cell responses. In addition, TLR stimulation with PAMPs has been reported to enhance T cell functions in a cell-autonomous manner (2). However, direct effects on T cell responses, either positive or negative, by DAMPs have not been demonstrated.
Sialic acid-binding immunoglobulin-like lectins (Siglecs) have immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or ITIM-like regions in their intracellular domains and negatively regulate, i.e., suppress, innate or B cell immune responses (3) (4) (5) (6) . They play a pivotal role in suppressing DAMP-mediated innate inflammatory responses (7) (8) (9) and in inducing B cell tolerance (6, 10) . However, whether Siglecs, specifically, Siglec-G, are expressed by T cells and if so, whether they have T cell-autonomous functions, and furthermore whether such a function can be targeted to mitigate in vivo pathological processes, remain unknown.
In allogeneic hematopoietic stem cell transplantation (all-HCT), host tissue injuries caused by underlying disease and conditioning regimens lead to the release of proinflammatory cytokines (11) , DAMPs (12, 13) , and PAMPs (14) . Both DAMP-and PAMP-mediated activation of APCs (12, 13, 15) has been shown to aggravate acute GVHD (16, 17) . Suppression of DAMP-mediated effects on APCs by Siglecs on hematopoietically derived APCs is crucial for controlling GVHD (18) . However, whether suppression of DAMP effects specifically and directly only on T cells can also affect GVHD is not known.
The role of negative regulators or suppressors of the damage-associated molecular patternmediated (DAMP-mediated) stimulation of innate immune responses is being increasingly appreciated. However, the presence and function of suppressors of DAMP-mediated effects on T cells, and whether they can be targeted to mitigate T cell-dependent immunopathology remain unknown. Sialic acid-binding immunoglobulin-like lectin G (Siglec-G) is a negative regulator of DAMP-mediated responses in innate immune cells, but its T cell-autonomous role is unknown. Utilizing loss-of-function-based (genetic knockout) and gain-of-function-based (agonist) approaches, we demonstrate that in the presence of certain DAMPs, Siglec-G suppressed in vitro and in vivo T cell responses. We also demonstrate that its T cell-autonomous role is critical for modulating the severity of the T cell-mediated immunopathology, graft-versus-host disease (GVHD). Enhancing the Siglec-G signaling in donor T cells with its agonist, a CD24Fc fusion protein, ameliorated GVHD while preserving sufficient graft-versus-tumor (GVT) effects in vivo. Collectively, these data demonstrate that Siglec-G is a potentially novel negative regulator of T cell responses, which can be targeted to mitigate GVHD.
Results
T cells express Siglec-G and it represses their responses in the presence of DAMPs. It remains unknown whether T cells respond to DAMPs. We made the potentially novel observation that naive T cells from B6 WT animals expressed the negative regulator of DAMP responses, Siglec-G mRNA ( Figure 1A ). We next examined whether naive T cells express Siglec-G protein by FACS using a monoclonal antibody against Siglec-G (clone SH2.1). To this end, we used Siglec-G-deficient (Siglec-G -/-) T cells as negative controls, B cells as positive controls, and antibody titrations from 100-to 1,000-fold dilution and found that in contrast to some previous reports (19, 20) , but consistent with another report (5) , that about 16% ± 2.6% of naive T cells expressed Siglec-G protein ( Figure 1B and Supplemental Figure 1 , A-G; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.92293DS1).
We next analyzed the Siglec-G-deficient B6 animals to determine whether Siglec-G is essential for T cell development or differentiation at homeostasis. Absence of Siglec-G did not affect the numbers or distribution of naive, central memory, effector memory, and Treg cells (Supplemental Figure 2 , A-H). We then examined whether Siglec-G had any functional effect on naive T cells. Siglec-G -/naive T cells showed proliferation similar to that of WT T cells in vitro following stimulation with anti-CD3/CD28 antibodies or allogeneic BALB/c-derived bone marrow-derived DCs (BMDCs) ( Figure 1 , C and D). Because Siglec-G is an important negative regulator of stimulation by DAMPs (3, 4) , we next determined whether the absence of Siglec-G on naive T cells affected their proliferative responses in the presence of DAMPs. To determine this, and to rule out indirect effects of DAMPs in APCs, we added high mobility group box 1 protein (HMGB-1), a well-characterized DAMP, to anti-CD3/CD28 antibody-mediated stimulation of T cells. Siglec-G -/-T cells exhibited significantly greater proliferation in the presence of HMBG-1 when compared with Siglec-G -/-T cells without DAMPs or the WT T cells regardless of the presence of DAMPs ( Figure  1E and Supplemental Figure 3A ). The WT T cells exhibited greater expression of Siglec-G when treated with the DAMP HMBG-1 ( Figure 1F ). These data collectively suggest that DAMP stimulation enhances the expression of its negative regulator Siglec-G, in the absence of which they show more enhanced T cell expansion. The negative signaling by the Siglec-G ITIM is mediated by its phosphorylation through recruitment of SHP-1 and SHP-2. Therefore, we next examined whether T cells, when stimulated in the presence of the DAMP HMBG-1, changed the ratios of SHP-1 and SHP-2 to phosphorylated SHP-1 (p-SHP-1) and p-SHP-2. When compared with WT T cells, upon stimulation the expression of p-SHP-1 and p-SHP-2 was reduced in the Siglec-G -/-T cells (Figure 1 , Supplemental Figure 3D , and Supplemental Figure 4 , A-C). By contrast, p-signal transducer and activator of transcription 3 (STAT3) was increased in both WT and Siglec-G -/-T cells, albeit to a greater extent in the KO than WT cells, but no such increase was observed in the activating signaling pathways such as in expression of lymphocyte-specific protein tyrosine kinase (LCK) in the presence of HMBG-1 (Supplemental Figure 3 , B and C). Furthermore, in the presence of the DAMP HMBG-1, Siglec-G -/-T cells showed higher activation, but showed similar expression of exhaustion markers such as programmed cell death protein 1 (PD-1) ( Figure 1H ), T cell immunoreceptor with Ig and ITIM domains (TIGIT), or lymphocyte-activation gene 3 (Lag3) (Supplemental Figure 3 , E and F) when compared with WT T cells. These data suggest that in the presence of DAMPs, Siglec-G/ITIM signaling was increased without an increase in activation signaling or the exhaustion markers.
Siglec-G regulates in vivo T cell responses in a cell-autonomous manner. We next determined whether deficiency of Siglec-G on T cells altered their responses in vivo, in the presence of DAMPs and lymphopenia both with and without non-self antigen-driven TCR stimulation. Because host tissue injuries caused by the conditioning regimen lead to the release of DAMPs (12, 13, 18) , we used lethally irradiated hosts to generate DAMPs from radiation-induced damage. The congenic B6 WT hosts were lethally irradiated and transplanted with naive T cells from syngeneic B6 WT or Siglec-G -/donors to determine whether absence of Siglec-G would alter T cell responses in vivo in the presence of DAMPs and lymphopenia, but in the absence of non-self antigen-driven TCR stimulation. Donor T cell expansion and activation (CD69 + ) in the spleen and intestinal epithelial cells (IELs) was similar in both the recipients of WT and Siglec-G-deficient syngeneic animals (Supplemental Figure 5 , A-C). These data suggested that in the absence of antigen-driven TCR stimulation, deficiency of Siglec-G did not lead to alteration of in vivo T cell responses when compared with WT T cells. We next determined whether Siglec-G regulates in vivo T cell responses following antigen-driven T cell stimulation (allostimulation) in the presence of DAMPs. We utilized, once again, lethal irradiation as conditioning regimen to release DAMPs (12, 13, 18) and we tested the hypothesis that Siglec-G -/donor T cells will show enhanced proliferation in the context of release of DAMPs and allostimulation. We utilized the (C) Isolated splenic CD90.2 + T cells from either B6 WT or Siglec-G -/animals were incubated with anti-CD3 (2 μg/ml) and anti-CD28 (1 μg/ml) antibodies for 48 hours and analyzed for proliferation following 3 H-thymidine incorporation during the last 6 hours of incubation. (D) In vitro mixed lymphocyte reaction (MLR). Isolated splenic CD90.2 + T cells from either B6 WT or Siglec-G -/animals were cultured with bone marrow-derived DCs derived from syngeneic B6 or allogeneic BALB/c animals for 96 hours and analyzed for proliferation following 3 H-thymidine incorporation during the last 16 hours of incubation (P = not significant [NS] between groups). (E-I) Isolated splenic CD90.2 + T cells from either B6 WT or Siglec-G -/animals were incubated with anti-CD3 (2 μg/ml) and anti-CD28 (1 μg/ml) antibodies in the presence or absence of HMBG-1 (10 μg/ml) for 24 hours and analyzed for proliferation following 3 Figure 6 , A and B). To confirm that the increased expansion of allogeneic B6 Siglec-G -/-T cells in the context of DAMP-induced inflammation is a cell-autonomous effect, we next mixed B6 WT (CD45.1 + ) and B6 Siglec-G -/-(CD45.2 + ) T cells in a 1:1 ratio and transferred them into allogeneic BALB/c animals following lethal irradiation. The donor T cells were harvested on day 4 after transfer. The CD45.2 + B6 Siglec-G -/-T cell demonstrated greater expansion than CD45.1 + B6 WT T cells ( Figure 2G ), demonstrating that the increased recovery was because of a cellautonomous effect of the absence of Siglec-G on T cells.
Absence of Siglec-G on donor T cells exacerbates GVHD. We next determined whether the increased expansion of alloreactive Siglec-G + T cells in the irradiated host was sufficient to alter T cell-dependent clinical outcome after allo-BMT, namely GVHD. We utilized the similarly conditioned and MHC-disparate B6→BALB/c model as above with 0.75 × 10 6 donor T cells from the WT or KO donors. The greater response of Siglec-G + T cells in the recipient animals was associated with exacerbated GVHD clinical severity and mortality ( Figure 3A ) when compared with the allorecipients that received WT T cells. To determine the magnitude of impact of the absence of Siglec-G on donor T cells on GVHD, we once again utilized the donor-recipient model as above, but this time increased the dose of the donor T cells (2 × 10 6 ). While the increase in donor T cells enhanced mortality in WT T recipients, the Siglec-G-deficient donor T cells still showed significantly greater GVHD mortality ( Figure 3B ). The enhanced mortality of the allogeneic B6-Siglec-G -/animals was associated with higher serum levels of IFN-γ and IL-17 ( Figure 2F and Supplemental Figure 6C ), as well as more severe GVHD-specific histopathological damage of the target organs liver, GI tract, and lungs ( Figure 3 , C and D, and Supplemental Figure 6D ). To eliminate straindependent factors, we utilized other BMT models wherein DAMPs are released as a consequence of conditioning by irradiation, namely the MHC-matched but multiple minor antigen-mismatched B6→BALB/b and the haploidentical B6→B6D2F1 models. In all of these multiple systems, the allorecipients that received B6 Siglec-G -/-T cells demonstrated significantly worse GVHD mortality and histopathological damage than those that received T cells from B6 WT animals (Figure 3 , E-G).
Next, to confirm in vivo that the effect of Siglec-G on T cells following their TCR stimulation was relevant only in the presence of DAMPs, we next utilized the nonirradiated (i.e., absence of condition-related damage and DAMP release) B6→B6D2F1 BMT model. In contrast to the irradiated allo-BMT models, the allogeneic Siglec-G -/animals demonstrated a similar mortality when compared with WT controls ( Figure 3H ).
Siglec-G does not alter Treg-mediated suppression. We next explored potential mechanisms. It is possible that absence of Siglec-G might reduce Treg-intrinsic functions, leading to enhanced responses of conventional naive T cell responses. Therefore, we explored whether the enhanced conventional naive T cell function was dependent on Tregs. As shown in Figure 4A , the in vitro functions of WT and Siglec-G -/-Tregs were equivalent in limiting proliferation of WT or Siglec-G -/naive T cells, suggesting that Siglec-G expression is not critical for their suppressive function. Consistent with these in vitro observations, the allogeneic recipients that received Siglec-G -/donor T cells demonstrated a significantly greater mortality than those that received WT T cells even when the CD4 + CD25 + T cells were depleted from the donor inoculum ( Figure 4B ). These data demonstrate that the enhanced response of Siglec-G-deficient naive T cells is not because of loss of Treg suppressive functions.
Interaction of Siglec-G on T cells with CD24 is critical for repressing DAMP-mediated amplification of their responses. To further dissect potential mechanisms, we next focused on the APC-Siglec-G interaction because CD24 directly binds a broad range of DAMPs, and also binds to Siglec-G and then represses the responses to DAMPs (7, 8, 21) . We hypothesized that if the APC CD24 interaction with donor T cell Siglec-G is critical, then the absence of CD24 on host APCs would enhance GVHD. Consistent with this hypothesis, the CD24 -/-APCs demonstrated a significantly greater capacity for stimulation of allogeneic WT T cells than WT APCs ( Figure  5A ). We next examined the functional relevance of the CD24-Siglec-G interaction during the development of GVHD in vivo and found that, as hypothesized, allogeneic CD24 -/animals demonstrated a significantly greater mortality than allogeneic WT controls ( Figure 5B ) in the B6→BALB/c model.
Siglec-G agonist mitigates GVHD. Next, to confirm that the interaction between Siglec-G on donor T cells and CD24 on host cells is critical for controlling GVHD, we utilized a novel CD24Fc fusion protein that consists of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain (7) and serves as a direct agonist to Siglec-G, to enhance the CD24-Siglec-G interaction (7) . We treated the recipients with CD24Fc on day 0 (5 mg/kg) in the B6→BALB/c model. Consistent with a previous report (18), we found that B6 WT animals treated with CD24Fc showed a significant amelioration of GVHD (Supplemental Figure 7, A and B) . We next confirmed that CD24Fc was stimulating Siglec-G and enhanced the negative ITIM signaling pathway. When allogeneic WT donor T cells were harvested on day 7 after treatment with CD24Fc and BMT, the p-SHP-1 was enhanced only in the donor T cells from the animals that were treated with the CD24Fc fusion protein ( Figure 5C and Supplemental Figure 8 ).
Next, to further confirm the specificity of the interaction of CD24Fc with Siglec-G, we lethally irradiated and transplanted the BALB/c CD24 -/animals with T cells from either B6 WT or B6 Siglec-G -/animals, which disrupted the interaction between Siglec-G and CD24. Administration of the CD24Fc significantly reduced GVHD in the animals that received T cells from B6 WT ( Figure 5D ) but not B6 Siglec-G -/animals ( Figure 5E ). Furthermore, administration of CD24Fc still significantly ameliorated GVHD in the absence of CD24 in both APCs and T cells (but had intact Siglec-G) ( Figure 5F ). These data collectively demonstrate that engagement of Siglec-G on donor T cells by CD24Fc controls DAMP-mediated aggravation of GVHD (Supplemental Table 1 ).
We next determined the putative translational potential of this approach to clinical allo-BMT following myeloablative conditioning. To this end, we next explored whether CD24Fc adds value as an adjuvant to the currently used clinical immune prophylaxis in humans, the calcineurin inhibitor tacrolimus. When CD24Fc was administered as above, along with daily treatment of tacrolimus, addition of CD24Fc significantly improved GVHD severity and mortality ( Figure 5G ).
Effect of enhancing Siglec-G responses with CD24Fc on GVT responses. Because GVHD is tightly linked with the graft-versus-tumor (GVT) effect and HMBG-1 released from necrotic or dying cancer cells is critical for the activation of tumor antigen-specific T cells (22) , we next explored whether decreasing donor T cell responses to DAMPs by enhancing the Siglec-G-CD24 interaction substantially altered the GVT responses. We utilized the same model of CD24Fc treatment as above, but added P815 at the time of BMT. Interestingly, CD24Fc-treated animals showed equivalent GVT response to nontreated animals ( Figure 6 , A-C). Similar GVT responses were also observed at a higher dose (5 × 10 2 /mouse) ( Figure 6D ) and in a second tumor model (A20 tumor cells) ( Figure 6E ). In addition, T cells isolated from CD24Fc-treated animals as well as nontreated animals showed equivalent killing of allogeneic P815 tumors in an ex vivo T cell cytotoxic killing assay ( Figure 6F ).
Taken together, these data demonstrate that the administration of CD24Fc mitigates GVHD while maintaining a sufficient GVT effect in these models. It is, however, important to note that these data still do not demonstrate whether the magnitude of GVT effects may be compromised, especially in instances where the tumors are less immunogenic or more rapidly proliferating.
Siglec-10 is expressed by human T cells and controls in vitro responses.
To demonstrate potential human clinical relevance of enhancement of the Siglec-G-CD24 interaction as a strategy to mitigate GVHD that is aggravated by GVHD, we explored whether human T cells expressed the ortholog of Siglec-G, namely Siglec-10 (23). The naive CD3 + T cells from human peripheral blood mononuclear cells (PBMCs) expressed Siglec-10 on 3.3% ± 2.5% of total T cells ( Figure 7A ). Interestingly, CD24Fc dramatically decreased the nonspecific TCR responses when PBMCs were incubated either during or before with HMBG-1 ( Figure 7B ). However, reduced nonspecific TCR responses with HMBG-1 were completely eliminated when Siglec-10-depleted PBMCs were used ( Figure 7C ), suggesting that Siglec-10, the human ortholog of murine Siglec-G, has similar effects on T cell responses only in the presence of DAMPs. These data nonetheless do not indicate the relevance of Siglec-10 in the absence of DAMPs or its relevance in comparison with other T cell checkpoint molecules. 
Discussion
Most investigations exploring the functions and impact of DAMPs have focused on the innate arm of the immune responses. Those that focused on negative regulatory effects of Siglecs focused only on innate immunity or on B cell-intrinsic functions (3, 6, 24, 25) . However, the roles of DAMPs and Siglecs in T cell biology remain unexplored. Our data collectively demonstrate for the first time, to our knowledge, that T cell responses in the presence of DAMPs can be repressed by Siglec-G in a cell-autonomous manner. This direct repression of enhanced T cell responses in the presence of DAMPs can be targeted to mitigate the T cell-mediated in vivo immunopathology, GVHD. This effect was at least in part dependent on the interaction of Siglec-G on T cells with CD24-expressing APCs. These data extend previous observations of the role of the CD24-Siglec axis on host APCs in the biology of GVHD. CD24 is broadly expressed in hematopoietically derived cells, immature neuronal cells, and epithelial cells (26) . Given the complexity and number of cell types involved in inducing and amplifying GVHD, whether Siglec expression on donor or host B cells or other cells will affect acute GVHD remains to be explored (27, 28) .
CD24 is reported to be expressed in solid tumors (29) and associated with tumor growth and metastasis (30, 31) caused by p53 inactivation (32) . Therefore, CD24 stimulation might potentially increase the risk of relapse and cause unexpected toxicities. However, our data demonstrate that enhancing Siglec-G responses with CD24Fc, a novel clinical grade fusion protein, mitigated GVHD but retained sufficient GVT responses. Additionally, CD24Fc enhanced GVHD reduction even in animals receiving calcineurin inhibitors, suggesting that this could be a novel approach as an adjunct to current clinical practice. The GVT models, while useful, are not entirely reflective of clinical situations and have model-specific limitations. We also demonstrate that Siglec-10, an ortholog of Siglec-G, is expressed on a subset of human T cells that plays an important role in prevention of enhancement of T cell responses by DAMPs. Nonetheless, when taken collectively our data suggest that addition of CD24Fc targeting the DAMP-dependent T cell responses could be a novel strategy to mitigate GVHD that could be explored in carefully designed clinical trials.
Both PAMPs and DAMPs amplify GVHD, but Siglec-G specifically appears to repress only DAMPmediated amplification of T cell responses, consistent with observations of Siglec-G on repressing DAMP-specific responses of innate immune cells (18) . Thus, targeting Siglec-G/CD24 pathways may be selective against DAMP-mediated inflammation that amplifies effector T cell responses. Furthermore, because the CD24-Siglec-G interaction has only been associated with regulating DAMP but not PAMP responses, it is tempting to speculate that the utilization of CD24Fc in the context of allogeneic hematopoietic cell transplantation (allo-HCT) may not increase infectious complications while reducing DAMP-associated aggravation of GVHD. Thus, Siglec-G has T cell-autonomous effects in repressing DAMP-mediated amplification of their responses. When taken together with our previous observations (18) , these data show that Siglec-G is an important regulator of inflammatory responses to tissue injuries, and these results provide a strong rationale for targeting negative regulatory pathways such as the Siglec-G/CD24 axis as a strategy for reducing GVHD.
Methods
Mice. C57BL/6 (B6, H-2 b , CD45.2 + ), B6D2F1 (H-2 b/d ), C3H.sw (H-2 b ), and BALB/b (H-2 b ) mice were purchased from the Jackson Laboratory. BALB/c (H-2 d ) mice were purchased from Charles River Laboratories. B6 Ly5.2 (H-2 b , CD45.1 + ) mice were purchased from NCI-Frederick. B6-background Siglec-G -/-GFP +/+ and CD24 -/have been described previously (5, 33) and were provided by Pang Zheng and Chen Liu (Children's National Medical Center). To make BALB/c CD24 -/animals, the CD24-null allele was backcrossed to the BALB/c background by marker-assisted speed breeding for 5 generations to eliminate all B6-specific genetic markers. All animals were cared for according to regulations reviewed and approved by the University Committee on Use and Care of Animals of the University of Michigan, based on University Laboratory Animal Medicine guidelines.
menting Siglec-G with CD24Fc improves tacrolimus-induced protection of experimental graft-versus-host disease (GVHD). BALB/c WT animals were lethally irradiated with 8.5 Gy and infused with 0.75 × 10 6 CD90 + T cells along with 5 × 10 6 TCD-BM cells from either syngeneic BALB/c WT or allogeneic MHC-mismatched B6 donors. The recipients were injected with CD24Fc (5 mg/kg) or diluent control on day 0 and treated with tacrolimus (0.005 mg/ kg, i.p.) for 14 days. n = 6-15 per group, pooled from 3 experiments. Kaplan-Meier method, **P < 0.01, when control versus CD24Fc plus tacrolimus treatment group and *P < 0.05, when tacrolimus versus CD24Fc treatment groups were compared.
BMT. BMTs were performed as previously described (18, 34, 35) . Briefly, splenic T cells from donors were enriched, and the BM was depleted of T cells by autoMACS (Miltenyi Biotec) utilizing CD90.2 microbeads (Miltenyi Biotec). We used well-established multiple BMT models. BALB/c, B6D2F1, C3H.sw, and BALB.B-WT animals were used as recipients and received either 8.5 Gy (BALB/c and BALB.B), 10.5 Gy (C3H.sw), or 11 Gy (B6D2F1) ( 137 Cs source) on day -1 and 0.75 × 10 6 (B6→BALB/c), 1 × 10 6 (B6→C3H.sw), 3 × 10 6 (B6→B6D2F1), and 4 × 10 6 (B6→BALB.B) CD90.2 + T cells along with 5 × 10 6 TCD-BM cells from either syngeneic or allogeneic donors. In a Treg-depleted BMT model, T cells were isolated from spleen and purified utilizing a Pan-T Cell Isolation Kit (Miltenyi Biotec). Isolated T cells were incubated with CD25 microbeads (Miltenyi Biotec) and depleted on a magnetic column. BALB/c animals received 1 × 10 6 CD25 -/-T cells along with 5 × 10 6 TCD-BM on day 0. In the nonirradiated BMT model, recipient B6D2F1 animals received 50 × 10 6 splenocytes from syngeneic B6D2F1, allogeneic B6 WT, or Siglec-G -/animals on day 0.
Systemic and histopathological analysis of GVHD. We monitored survival after allo-HCT daily and assessed the degree of clinical GVHD weekly, as described previously (36) . Histopathological analysis of the liver, GI tract, and lung, which are the primary GVHD target organs, was performed as previ- ously described (37) utilizing a semiquantitative scoring system implemented by a single pathologist (Chen Liu) (37) . After scoring, the codes were broken, and the data were compiled.
DC cultures. To obtain DCs, BM cells from B6 WT or BALB/c WT were cultured with murine recombinant GM-CSF (20 ng/ml; PeproTech) for 7 days and harvested as described previously (38) . DCs were isolated by using CD11c (N418) MicroBeads (Miltenyi Biotec) and the autoMACS and utilized as stimulator for the mixed lymphocyte reaction (MLR) and Treg suppression assay.
FACS analysis. FACS analyses were performed as previously described (38, 39) . Briefly, to analyze donor T cell expansion and activation markers, splenocytes from transplant-recipient mice were resuspended in FACS wash buffer (2% BSA in PBS) and stained with the following conjugated mAbs: PerCP-Cy5.5-conjugated mAbs against mouse CD4 (clone GK1.5) and CD8 (clone 53-6.7); PE-conjugated mAbs against mouse CD69 (clone H1.2F3), CD183 (CXCR3) (clone CXCR3-173), LPAM-1 (integrin α4β7) (clone DATK32), CD62L (clone MEL-14), and TIGIT (clone 1G9); APC-conjugated mAbs against mouse H-2K b (clone AF6-88.5), CD44 (clone IM7), PD-1 (clone 29F.1A12), and Lag3 Human peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll and cultured on anti-CD3 mAb-precoated dishes along with anti-CD28 mAb and HMGB-1 for 48 and 72 hours. Cells were harvested and stained for human CD3 and Siglec-10. (A) Left: A representative FACS plot of Siglec-10 expression in CD3 + T cells. Right: Siglec-10 expression in naive CD3 + T cells of PBMCs (n = 7). (B) Proliferation of PBMCs incubated with anti-CD3 and anti-CD28 mAbs in the presence or absence of HMGB-1 with CD24Fc for 48 hours and analyzed for proliferation following 3 H-thymidine incorporation during the last 6 hours of incubation. Paired analysis of CD24Fc treatment of human PBMCs is shown. Left: Anti-CD3/CD28 stimulation along with HMGB-1 (n = 7). Right: Pretreated with HMGB-1 and anti-CD3/CD28 stimulation (n = 6). Paired t test, *P < 0.05, **P < 0.02, ***P < 0.01, ****P < 0.002 showed significant reduction between nontreatment and CD24Fc treatment. (C) Human Siglec-10-depleted PBMCs were isolated with Ficoll and MACS and cultured on anti-CD3 mAb-precoated dishes along with anti-CD28 mAb and HMGB-1 for 48 hours and analyzed for proliferation following 3 H-thymidine incorporation during the last 6 hours of incubation. Paired analysis in CD24Fc treatment of human PBMCs is shown. Left: Anti-CD3/CD28 stimulation along with HMGB-1 (n = 7). Right: Pretreated with HMGB-1 and anti-CD3/CD28 stimulation (n = 6). No Tx, no treatment.
Western blot analysis. T cells were incubated with anti-CD3 (2 μg/ml) and CD28 (1 μg/ml) antibody with or without HMBG-1 (10 μg/ml) in 24-well plates for 3, 6, 12, and 24 hours. Following incubation, T cells were harvested and washed with PBS and then whole-cell lysates were obtained and protein concentrations determined with a Pierce BCA Protein Assay (Thermo Fisher Scientific). Equal amounts of protein were separated by 10% SDS-PAGE gel (120 V, 1.5 hours) and subsequently transferred to nitrocellulose membranes (20 V, 1 hour). The following antibodies were used to analyze the membranes: anti-rabbit STAT-3 (79D7), anti-rabbit p-STAT-3 (Y705), anti-rabbit LCK, and antirabbit p-LCK (Y505) purchased from Cell Signaling Technology. Secondary antibodies conjugated to HRP (Jackson ImmunoResearch) were used to detect primary antibodies. Densitometric analysis was performed using ImageJ software (NIH). For testing SHP-1 and p-SHP-1 expression, T cells were harvested at day 7 after BMT and whole-cell lysates were prepared as described above. Briefly, cell pellets were washed twice with cold PBS, resuspended in cell lysis buffer (20 mM Hepes, pH 7.9 with 400 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 1 μg/ml pepstatin A, 10 μg/ ml leupeptin, and 10 μg/ml aprotinin). Protein concentration was quantified, and equivalent amounts of protein sample (10-20 μg) were electrophoresed in NuPAGE Novex 4%-12% Bis-Tris gels, and transferred to PVDF membranes, followed by incubation with primary antibodies (polyclonal rabbit anti-pp-SHP-1, total SHP-1, β-actin, Cell Signaling; 1:1,000) and appropriate secondary antibodies. The bands were visualized by using a Pierce enhanced chemiluminescence system, and analyzed by densitometry. p-SHP-1 levels were normalized to that of total SHP-1/2 bands, respectively. Each result represents the average value of 2 independent experiments ± standard deviation.
Treatment with CD24 fusion protein.
In the in vivo experiments, the BALB/c WT and CD24 -/-BALB/c animals received 850 cGy total body irradiation ( 137 Cs source) on day -1 and then received an intravenous injection of 5 × 10 6 BM cells plus isolated 0.75 × 10 6 CD90 + T cells from a donor on day 0. CD24Fc, comprising the extracellular domain of CD24 and IgG Fc (provided by OncoImmune) (5 mg/kg) and an equivalent dose of PBS were administered i.p. on day 0 of all-HCT (40) .
Induction of leukemia and lymphoma. Tumors (P815, H-2 d ) were purchased from American Type Culture Collection (ATCC) and introduced during BMT at 2 different doses as described previously (41) . To observe GVT responses, we utilized the lower dose of tumor cells (P815, 1 × 10 3 to 5 × 10 3 /mouse) because even at this low dose we already established that the animals cannot reject the tumor cells and that this tumor is uniformly lethal and results in tumor infiltration and engraftment of the liver and spleen with characteristic nodule formation or hind-limb paralysis caused by spinal cord infiltration (41) . We concluded that tumor contributed to death only if the tumor was present at the necropsy. Death was attributed to GVHD alone only if no tumor was evident and there was histologic evidence of GVHD. Mice surviving beyond the observation period of BMT were sacrificed for histological evaluation to determine leukemia-and lymphoma-free survival.
Bioluminescence imaging. Bioluminescence imaging was performed with a cryogenically cooled CCD camera (IVIS, Caliper Life Sciences). Acquisition and analysis of images were performed as previously described (41) . All animals were imaged 10 minutes after being injected i.p. with 100 μl (40 mg/ml) of firefly D-luciferin (Biosynth International Inc.). Animals were imaged 30 seconds to 5 minutes, depending on the signal strength. All animals were maintained under isoflurane anesthesia and in a 37°C environment. 51 Cr-release assay. Donor splenocytes from the recipient animals were harvested and normalized for donor CD8 + T cells and then utilized directly as effector cells. MBL-2 (H-2 b for syngeneic) and P815 (H-2 d for allogeneic) were labeled (2 × 10 6 cells) with 2 MBq Na 2 51 CrO 4 (PerkinElmer Life) for 1.5 hours at 37°C in a 5% CO 2 atmosphere and used as target cells. After washing, 5 × 10 3 labeled targets were resuspended and the 51 Cr-release assay was performed. These preparations were added to triplicate wells at varying effector-to-target ratios and incubated for 4 hours. Maximal and background release was determined by the addition of Triton X-100 (Sigma-Aldrich) or media alone to targets, respectively. 51 Cr activity in supernatants taken 4 hours later was determined in an autogamma counter (Packard).
Human PBMC isolation. Studies with human cells were performed after obtaining informed consent from the participants; informed consent was obtained in accordance with the Declaration of Helsinki. The University of Michigan Institutional Review Board approved the studies (approval number, HUM0043287). Peripheral blood samples were collected from participants and then isolated with utilizing Ficoll-Paque PREMIUM solution (GE Healthcare Bio Science). In some experiments, Siglec-10depleted PBMCs were obtained by purification with APC-conjugated mAbs against human Siglec-10 (clone 5G6, Miltenyi Biotec) and anti-APC microbeads by MACS. PBMCs (1 × 10 6 /ml) were plated
